Metabolomics for Mechanism of Action: Understanding Drivers of Synergistic Inhibitor Treatment in Cancer
Metabolomics for Mechanism of Action in Synergistic Cancer Treatments Next-Generation Metabolomics can provide robust, biologically meaningful data for drug combination analysis. Learn more about treatment-induced metabolic reprogramming and targeted combination...
Untargeted Metabolomics Reimagined: Meet MassID™
What if untargeted metabolomics delivered on its promise? For years, untargeted metabolomics has been one of the most compelling approaches in biology: measure broadly, capture molecular diversity and improve biological interpretation and understanding. In practice,...
PRMT5 Metabolomics Panel for Patient Stratification
PRMT5 Metabolomics Panel for Patient Stratification This poster presents a targeted, multiplexed LC-MS/MS metabolomics assay developed to support patient stratification and pharmacodynamic monitoring for MTA-cooperative PRMT5 inhibitors in oncology research....